M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer

Phase 3

Completed

Conditions: Neurotoxicity
Unspecified Childhood Solid Tumor, Protocol Specific
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: alpha-lipoic acid
Other: placebo

First Posted Date: 2005-06-03

Last Posted Date: 2014-04-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 244

Registration Number: NCT00112996

Locations: 🇺🇸
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Fort Smith, Arkansas, United States
🇺🇸
Cancer Research for the Ozarks, Springfield, Missouri, United States
🇺🇸
CCOP - Scott and White Hospital, Temple, Texas, United States

and more 10 locations

Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer

Phase 1

Terminated

Conditions: Ovarian Cancer

Interventions: Biological: Intraperitoneal tgDCC-E1A
Drug: Paclitaxel

First Posted Date: 2005-02-01

Last Posted Date: 2018-11-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT00102622

Locations: 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 1

Terminated

Conditions: Head and Neck Cancer

Interventions: Drug: Fenretinide (4-HPR)
Drug: SCH66336

First Posted Date: 2005-02-01

Last Posted Date: 2018-11-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00102635

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Campath-1H

First Posted Date: 2005-02-01

Last Posted Date: 2012-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00102661

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide

Phase 1

Active, not recruiting

Conditions: Recurrent Glioblastoma
Malignant Supratentorial Neoplasm
Recurrent Gliosarcoma

Interventions: Drug: Lonafarnib
Drug: Temozolomide

First Posted Date: 2005-02-01

Last Posted Date: 2024-10-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 34

Registration Number: NCT00102648

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: Filgrastim
Biological: Pegfilgrastim
Biological: Rituximab
Drug: Cyclophosphamide
Drug: Pegylated liposomal doxorubicin hydrochloride
Drug: Prednisone
Drug: Vincristine Sulfate

First Posted Date: 2005-01-10

Last Posted Date: 2020-10-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT00101010

Locations: 🇺🇸
CCOP - Grand Rapids, Grand Rapids, Michigan, United States
🇺🇸
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Fort Smith, Arkansas, United States
🇺🇸
CCOP - Kalamazoo, Kalamazoo, Michigan, United States

and more 4 locations

Trial of Curcumin in Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Neoplasms
Adenocarcinoma

Interventions: Drug: Curcumin

First Posted Date: 2004-10-19

Last Posted Date: 2020-08-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00094445

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer

Phase 2

Completed

Conditions: Anal Cancer

Interventions: Drug: Capecitabine
Drug: Oxaliplatin
Radiation: Radiation Therapy (XRT)

First Posted Date: 2004-10-08

Last Posted Date: 2023-04-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00093379

Locations: 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: Bleomycin Sulfate
Biological: Filgrastim
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Cisplatin
Drug: Doxorubicin Hydrochloride (DOX)
Drug: Fluorouracil
Drug: Leucovorin calcium
Drug: Etoposide
Drug: Pentamidine
Drug: Prednisone
Drug: Ifosfamide
Drug: Trimethoprim-Sulfamethoxazole
Drug: Methotrexate
Drug: Vincristine Sulfate
Drug: Methylprednisolone
Drug: Zidovudine (AZT)
Radiation: Radiation Therapy

First Posted Date: 2004-10-05

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 46

Registration Number: NCT00002524

Locations: 🇺🇸
MD Anderson Cancer Center Orlando, Orlando, Florida, United States
🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer

Phase 2

Withdrawn

Conditions: Metastatic Cancer
Liver Cancer

Interventions: Drug: Pyrazoloacridine

First Posted Date: 2004-09-14

Last Posted Date: 2012-02-22

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00003714

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy